IDH1 and cholangiocarcinoma: Although not yet recruiting, the NCT05814536 [96] trial will assess the safety and clinical efficacy of Safusidenib (AB-218), a selective IDH1 inhibitor, with the advantage of oral administration, in patients with IDH1mut advanced CCA and other solid tumors.